National Institute of Virology

Indian virology research institute

ICMR-National Institute of Virology
Established1952; 72 years ago (1952)
ChairSheela V. Godbole
Budget950 crore (US$120 million) (2021-2022)[1]
Location
Pune, Maharashtra, India
Websitehttps://niv.icmr.org.in/

The National Institute of Virology in Pune, India is an Indian virology research institute and part of the Indian Council of Medical Research (ICMR).[2] It was previously known as 'Virus Research Centre' and was founded in collaboration with the Rockefeller Foundation. It has been designated as a WHO H5 reference laboratory for SE Asia region.[3]

The Virus Research Centre (VRC), Pune came into existence in 1952 under the joint auspices of the ICMR and the Rockefeller Foundation, as a part of the global programme of investigations on the arthropod-borne group of viruses.[4] In view of its expanded scope and activities, the VRC was re-designated as the National Institute of Virology (NIV) in 1978.[4]

The NIV is identified today as the WHO Collaborating Centres for arboviruses reference and hemorrhagic fever reference and research. NIV is also the National Monitoring Centre for Influenza, Japanese encephalitis, Rota, Measles, Hepatitis and Coronavirus.[4]

History

The National Institute of Virology is one of the major Institutes of the Indian Council of Medical Research (ICMR).[4] It was established at Pune, Maharashtra, India in 1952 as Virus Research Centre (VRC) under the auspices of the ICMR and the Rockefeller Foundation (RF), USA.[4] It was an outcome of the global programme of the RF for investigating the Arthropod Borne viruses. Since the studies on arboviruses and their arthropod vectors involve most of the basic principles and techniques of general virology, entomology and zoology, these viruses were also considered to be an ideal group, to begin with, for intensive training and research in virology. The RF withdrew its support in 1967 and since then the institute has been funded by the ICMR.[4]

Entrance gate with name of institution illuminated on a banner on top
Gate of National Institute of Virology, Pune

The institute was designated as one of the collaborating laboratories of the World Health Organization (WHO) in 1967 and it started functioning as the regional centre of the WHO for South-East Asia for arbovirus studies from 1969. Since 1974, it has been functioning as a WHO collaborating centre for arbovirus reference and research. In 1995 it has been redesignated as the WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research and Rapid Diagnosis of Viral Diseases.[4]

NIV is also the National Centre for Hepatitis and Influenza.It has outstations in Bangalore, Kerala and Mumbai. The field unit of NIV at Bengaluru is one of the centres under National Polio Surveillance Programme conducting surveillance of acute flaccid paralysis cases from Karnataka as a part of Global Polio Eradication Programme of the WHO South-East Asia region since 1997. World Health Organization (WHO) Regional Collaborating Centre for Reference and Research on Arboviruses, Influenza and Measles as well as National Reference Centre for Hepatitis, Avian Influenza and emerging infectious diseases.[5]

The institute conducts an M.Sc. in Virology and a PhD course, under the aegis of the Savitribai Phule Pune University, Pune.[6]

Departments

Research areas include Cell repository, Electron microscopy, Rickettsioses, Hepatitis, Influenza and related viruses, Clinical virology, Biochemistry, Virus registry, and Biostatistics. The research activities of the Institute are coordinated by a Scientific Advisory Committee (SAC).[citation needed]

Achievements

On the recommendation of the SAC, the VRC acquired its status of national importance and was renamed as the National Institute of Virology (NIV) in 1978. Subsequently, studies on Acquired Immune Deficiency Syndrome (AIDS), Rotavirus gastroenteritis, acute haemorrhagic conjunctivitis, Rabies, Herpes simplex, Buffalo pox, Measles, and Poliomyelitis were also initiated.

A Microbial Containment Complex (MCC) having P-3 biosafety levels for handling microorganisms of highly infectious nature is being established at Pashan, 11 km off the main laboratory at Pune. The laboratory will provide a National Containment facility for the safe handling of hazardous pathogens.

Landmark achievements

  • Isolated the 11 strains of SARS-CoV-2 virus and helped India becoming the fifth country in world to isolate the strain[7]
  • First laboratory in the country that developed comprehensive infrastructure facilities like:
  • Discovery of Kyasanur Forest Disease (KFD) a tick borne viral disease, studying its natural cycle
  • Finding of a new genotype of dengue virus[8]
  • First institute to confirm the occurrence of many arboviral diseases in India, viz.,
  • Ecological studies to understand the natural cycle of zoonotic viruses like KFD, JE, and Chandipura (CHP) etc.
  • Discovered 22 new viruses; a few have been characterized fully, while others are partially characterized or unrecognized. Recently, isolated and characterized a novelvirus “Malsoor”, from frugivorous bats, belonging to Phleobovirus family.
  • Pioneering effort in outbreak and pandemic investigations and establishment of research group in Epidemiology. Over 250 epidemics investigated.
  • Conducted numerous serological surveys to create background information on prevalence of viral diseases in India.
  • Invaluable collection of sera and virus strains: Approx. 260,000 serum samples and >600 strains of viruses isolated from humans, animals and arthropods.
  • Discovered new species of arthropods: One new species of mosquito, 2 species of sand flies, 14 species of sucking lice, 2 species of fleas, 3 species of bugs, 18 species of ticks and 63 species of trombiculid mites.
  • Discovered one new species each of rodent and bat; and a subspecies of bird.
  • Developed the first mosquito cell line in the world: popularly called ‘the Singh's cell line’, a clone of which is now known as C6/36 (clone developed by A Igarashi), is used extensively for arboviral studies. Many new cell lines were also developed from fish and arthropods subsequently.
  • Developed Monoclonal antibodies against JE, Dengue, WN, Chikungunya, Influenza and respiratory syncytial viruses (RSV).
  • Developed indigenous ELISA for detection of JE, Dengue, WN, CHP, Hepatitis A, B, E, Rota, Measles and Crimean Congo Hemorrhagic Fever (CCHF) viruses
  • First visualization of Hepatitis E virus particles, confirmation of the virus as the causative agent of water bore hepatitis, characterization of clinical, epidemiological and immunological parameters for development of a candidate vaccine. (Technology ready for transfer to Industry).
  • Epidemiology and characterization of Hepatitis viruses, development of vaccines and diagnostic reagents.
  • Genotyping of important viruses like JE, WN, Dengue, Hepatitis, Measles, RSV etc.
  • Establishment of multisite Influenza surveillance network in 2004. Isolated numerous strains of influenza A and B viruses from humans and animals.
  • Establishment of Avian Influenza Department for investigation of Avian Influenza in India (2006) and pandemic Influenza investigation and policy making in 2009.
  • First detection of human meta-pneumovirus from acute pneumonia cases in India.
  • Discovered Chandipura virus involvement in encephalitis outbreaks in children in India.
  • Isolation of several strains of Rotaviruses. Established the utility of immune goat colostrum for prevention of diarrhea.
  • Vaccine trials for JE, KFD, measles, hepatitis etc.
  • Bangalore unit has been accredited as National Laboratory for Karnataka under National Polio Surveillance Program (NPSP) since 1997. In addition Gorakhpur and Kerala units have also been established.
  • Recently, played an important role in providing diagnostic services, training and support in developing a country-wide network for diagnostic facility and various national documents.
  • Development of an inactivated KFD vaccine for public health (Technology transferred to Karnataka state).
  • Development of an inactivated JE vaccine for public health (Technology transferred to Industry).
  • Establishment of Biosafety Level-4 laboratory dedicated for virus research. This is the first high tech laboratory in Asia.

Thrust Areas in viral diseases of public health importance

See also

References

  1. ^ "Budget 2021 cuts spending in health research, but extends lion's share to ICMR".
  2. ^ "Archived copy" (PDF). Archived from the original (PDF) on 5 May 2012. Retrieved 1 May 2012.{{cite web}}: CS1 maint: archived copy as title (link)
  3. ^ National Institute of Virology, Pune Archived 2 July 2009 at the Wayback Machine Indian Council of Medical Research (ICMR).
  4. ^ a b c d e f g "National Institute of Virology". Journal of Postgraduate Medicine. 46 (4): 299–302. 1 October 2000. ISSN 0022-3859. PMID 11435663.
  5. ^ "National Institute of Virology". Bioline International. Journal of Postgraduate Medicine, Vol. 46, No. 4, October–December, 2000, pp. 297-302. Retrieved 22 March 2020.{{cite web}}: CS1 maint: others (link)
  6. ^ "Emerging courses: Virology – all you need to know about courses, college and career options". The Indian Express. 29 April 2020.
  7. ^ Sharma, Neetu Chandra (13 March 2020). "India becomes fifth country to isolate Covid-19 virus strain". Livemint. Retrieved 13 March 2020.
  8. ^ "Scientists at National Institute of Virology discover new genotype of the Dengue virus". Tech2. 2 November 2017. Retrieved 22 March 2020.

External links

  • Official website
Pre-pandemic
2020
2021
2022
2023 and after
Africa
Northern
Eastern
Southern
Central
Western
Asia
Central/North
East
Mainland China
South
India
By location
Southeast
Malaysia
Philippines
West
Europe
United Kingdom
By location
Eastern
Western Balkans
European Union
EFTA countries
Microstates
North
America
Atlantic
Canada
Caribbean
Countries
British Overseas Territories
Caribbean Netherlands
French West Indies
US insular areas
Central America
United States
responses
By location
Oceania
Australia
New Zealand
South
America
Others
Culture and
entertainment
Arts and
cultural heritage
Education
By country
Sports
By country
By sport
Society
and rights
Social impact
Labor
Human rights
Legal
Minority
Religion
Economic
By country
By industry
Supply and trade
Financial markets
Information
Misinformation
Politics
Political impact
Protests
International relations
Language
Others
Health issues
Medical topics
Testing and
epidemiology
Apps
Prevention
Vaccines
Topics
Authorized
DNA
Inactivated
mRNA
Subunit
Viral vector
Virus-like particles
In trials
Attenuated
  • COVI-VAC (United States)
DNA
Inactivated
RNA
Subunit
Viral vector
Virus-like particles
Deployment
by location
Africa
Asia
Europe
North America
Oceania
South America
Others
Treatment
Monoclonal antibodies
Small molecule antivirals
Specific
General
Institutions
Hospitals and
medical clinics
Mainland China
Others
Organizations
Global
By location
Health
institutes
Pandemic
institutes
Relief funds
People
Medical
professionals
Researchers
Officials
WHO
  • Tedros Adhanom (Director-General of the WHO)
  • Bruce Aylward (Team lead of WHO-China COVID-19 mission)
  • Maria Van Kerkhove (Technical Lead for COVID-19 response)
  • Michael J. Ryan (Executive Director of the WHO Health Emergencies Programme)
By location
Others
Deaths
Data (templates)
Global
Africa
  • Algeria
  • Angola
  • Benin
  • Botswana
  • Burkina Faso
  • Burundi
  • Cameroon
  • Comoros
  • Egypt
  • Eswatini
  • Ethiopia
  • Ghana
    • cases chart
  • Ivory Coast
  • Kenya
  • Libya
  • Malawi
  • Mali
  • Mauritania
  • Mauritius
  • Morocco (including occupied Western Sahara)
  • Mozambique
  • Namibia
  • Nigera
    • cases chart
  • São Tomé and Príncipe
  • Senegal
  • Seychelles
  • Sierra Leone
  • South Africa
    • cases chart
  • South Sudan
  • Sudan
  • Tanzania
  • Togo
  • Tunisia
  • Uganda
  • Zambia
  • Zimbabwe
    • cases chart
Americas
  • Argentina
  • Bolivia
  • Brazil
  • Canada
    • by province
    • vaccinations by province
  • Chile
    • by commune
  • Colombia
  • Costa Rica
    • cases chart
  • Cuba
  • Dominican Republic
  • Ecuador
  • El Salvador
  • Guatemala
  • Haiti
  • Honduras
  • Mexico
    • cases chart
  • Nicaragua
  • Panama
  • Paraguay
  • Peru
  • United States
    • by state
  • Uruguay
  • Venezuela
Asia
  • Afghanistan
  • Armenia
    • Artsakh
  • Azerbaijan
  • Bahrain
  • Bangladesh
    • by division
  • Bhutan
    • cases chart
  • Brunei
  • Cambodia
    • cases chart
    • summary
  • China
    • cases chart
    • confirmed per capita
    • lockdowns
    • by province
    • Hong Kong
    • Macau
  • Cyprus
  • East Timor
  • Egypt
  • Georgia
  • India
  • Indonesia
    • cases chart
  • Iran
    • cases chart
  • Iraq
  • Israel
    • cases chart
  • Japan
    • cases chart
  • Jordan
  • Kazakhstan
  • Kuwait
    • cases chart
  • Kyrgyzstan
  • Laos
  • Lebanon
  • Malaysia
    • cases chart
    • charts
  • Myanmar
    • cases chart
    • summary
  • Nepal
    • cases chart
  • Oman
    • cases chart
  • Pakistan
    • cases chart
  • Philippines
    • cases chart
    • areas of quarantine
    • vaccinations chart
  • Qatar
  • Russia
    • cases chart
    • by federal subject
    • North Asia
  • Saudi Arabia
  • Singapore
  • South Korea
    • cases chart
    • vaccinations charts
  • Sri Lanka
  • Syria
  • Taiwan
    • vaccination charts
  • Tajikistan
  • Thailand
    • cases chart
  • Turkey
    • cases chart
  • United Arab Emirates
    • cases chart
  • Uzbekistan
    • cases chart
  • Vietnam
    • statistics charts
  • Yemen
Europe
  • Albania
  • Austria
    • cases chart
  • Belarus
  • Belgium
    • cases chart
  • Bosnia and Herzegovina
  • Bulgaria
    • cases chart
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
    • cases chart
    • Faroe Islands
  • Estonia
    • cases chart
  • Finland
  • France
    • cases chart
  • Germany
    • cases chart
  • Greece
  • Hungary
  • Iceland
    • cases chart
  • Ireland
    • cases chart
  • Italy
    • cases chart
    • statistics charts
    • vaccinations chart
  • Kosovo
  • Latvia
  • cases chart
  • Lithuania
    • cases chart
  • Luxembourg
  • Malta
  • Moldova
  • Monaco
  • Montenegro
  • Netherlands
  • North Macedonia
  • Norway
    • cases chart
  • Poland
    • cases chart
    • by voivodeship
  • Portugal
    • cases chart
  • Romania
  • cases chart
  • Russia
    • cases chart
    • by federal subject
    • North Asia
  • San Marino
  • Serbia
  • Slovakia
    • cases chart
    • by region
  • Slovenia
    • cases chart
  • Spain
    • cases chart
  • Sweden
    • cases chart
  • Switzerland
    • cases chart
  • Turkey
    • cases chart
  • Ukraine
  • United Kingdom
    • Scotland
      • 2020
      • 2021
    • Gibraltar
    • vaccinations chart
      • daily
      • by nation
  • Vatican City
Oceania
  • Australia
    • by state/territory
  • Fiji
  • French Polynesia
  • New Caledonia
  • New Zealand
  • Papua New Guinea
  • Solomon Islands
Others
  • Cruise ships
    • Diamond Princess
  • v
  • t
  • e
  • Timeline
    • 2020
      • January–May
      • June–December
    • 2021
  • Statistics
    • chart
Topics
Government response
Incidents
Locations
States
Union territories
Legal framework
Agencies and
institutes
Administration
Research
and testing
Public
Private
Vaccines
Others
Officials
Union government
State governments
Agency executives
virus icon COVID-19 portal
Authority control databases Edit this at Wikidata
International
  • ISNI
  • VIAF
National
  • United States